Zofia F. Bielecka

Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)

Zofia F. Bielecka, Anna M. Czarnecka, Wojciech Solarek et al. · Current Signal Transduction Therapy · 2014 · 80 citations · Full text

Medicine, Oncology, Pharmacology +12

LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2

Jeffrey D. Bradley, Shunichi Sugawara, K.H. Lee et al. · ESMO Open · 2024 · 71 citations · Full text

Medicine, Oncology, Radiation Oncology +17

PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer

Fabrice Barlési, Byoung Chul Cho, Sarah B. Goldberg et al. · Future Oncology · 2024 · 40 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells

Zofia F. Bielecka, Agata Malinowska, Klaudia Brodaczewska et al. · Cell & Bioscience · 2017 · 39 citations · Full text

Medicine, Oncology, Pharmacology +17

Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study

Jeffrey D. Bradley, Milada Zemanová, Virote Sriuranpong et al. · Journal of Clinical Oncology · 2025 · 31 citations · Full text

Medicine, Oncology, Pharmacotherapy +17